OA05.03 Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
Helena A. Yu(Memorial Sloan Kettering Cancer Center), Pasi A. Jänne(Harvard University), Benjamin Besse(Institut Gustave Roussy), Yasushi Goto(Tennessee Oncology), Paolo Bironzo(University of Turin), Pomy Shrestha(Daiichi Sankyo (United States)), Hidetoshi Hayashi(Kindai University), Martin Reck(German Center for Lung Research), M.L. Johnson(Sarah Cannon), Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Kiyotaka Yoh(National Cancer Center Hospital East), Y.-L. Wu(Cancer Institute (WIA)), P.-D. Fan(Daiichi Sankyo (United States)), James Chih‐Hsin Yang(National Taiwan University Hospital), Dalila Sellami(Daiichi Sankyo (United States)), S.-H. Lee(Samsung Medical Center), Enriqueta Felip(Institut Català d'Ornitologia), Qian Dong(Daiichi Sankyo (United States)), D.-W. Kim, M. Vigliotti(Daiichi Sankyo (United States)), David Sternberg(Daiichi Sankyo (United States))
Cited by 1
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k